DK2864359T3 - Anti-cd26-antistoffer og anvendelser deraf - Google Patents

Anti-cd26-antistoffer og anvendelser deraf Download PDF

Info

Publication number: DK2864359T3
Authority: DK; Denmark
Prior art keywords: antibodies; applications
Prior art date: 2013-02-19

Application number

DK14705767.3T

Other languages

English (en)

Inventor

Naro Antonio Francesco Di

Original Assignee

Adienne S A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-02-19

Filing date

2014-02-19

Publication date

2019-07-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48092884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2864359(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-02-19 Application filed by Adienne S A filed Critical Adienne S A

2019-07-22 Application granted granted Critical

2019-07-22 Publication of DK2864359T3 publication Critical patent/DK2864359T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Mycology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Transplantation (AREA)
Diabetes (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Fats And Perfumes (AREA)

DK14705767.3T 2013-02-19 2014-02-19 Anti-cd26-antistoffer og anvendelser deraf DK2864359T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP13425029.9A EP2767549A1 (en)	2013-02-19	2013-02-19	Anti-CD26 antibodies and uses thereof
PCT/EP2014/053243 WO2014128168A1 (en)	2013-02-19	2014-02-19	Anti-cd26 antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
DK2864359T3 true DK2864359T3 (da)	2019-07-22

Family

ID=48092884

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14705767.3T DK2864359T3 (da)	2013-02-19	2014-02-19	Anti-cd26-antistoffer og anvendelser deraf

Country Status (26)

Country	Link
US (2)	US9376498B2 (da)
EP (3)	EP2767549A1 (da)
JP (2)	JP6240195B2 (da)
KR (1)	KR101869589B1 (da)
CN (1)	CN104684931B (da)
AU (1)	AU2014220777B2 (da)
CA (1)	CA2874422C (da)
CY (1)	CY1121980T1 (da)
DK (1)	DK2864359T3 (da)
ES (1)	ES2738283T3 (da)
HR (1)	HRP20191277T8 (da)
HU (1)	HUE045150T2 (da)
IL (1)	IL237244B (da)
LT (1)	LT2864359T (da)
ME (1)	ME03753B (da)
MX (1)	MX357293B (da)
NZ (1)	NZ631111A (da)
PL (1)	PL2864359T3 (da)
PT (1)	PT2864359T (da)
RS (1)	RS59093B1 (da)
RU (1)	RU2662933C2 (da)
SA (1)	SA515360248B1 (da)
SI (1)	SI2864359T1 (da)
SM (1)	SMT201900408T1 (da)
TR (1)	TR201910572T4 (da)
WO (1)	WO2014128168A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11242399B2 (en) *	2013-02-19	2022-02-08	Adienne S.A.	Anti-CD26 antibodies
EP2767549A1 (en) *	2013-02-19	2014-08-20	Adienne S.A.	Anti-CD26 antibodies and uses thereof
LT3250202T (lt) *	2015-01-27	2021-06-25	SciPharm S.à r.l.	Kompozicija, skirta naudoti kraujodaros kamieninių ląstelių po transplantacijos prigijimo pagerinimui
US10630229B2 (en) *	2016-10-11	2020-04-21	Kevin Stapleton	Panel mounting bracket with grounding mid-clamp and related methods
KR101960414B1 (ko) *	2016-11-11	2019-03-27	대한민국	사람 유래 dpp-4 유전자를 이용한 당뇨 질환 모델용 형질전환돼지 및 이의 용도
TW201930880A (zh)	2017-12-22	2019-08-01	瑞士商艾迪安納股份有限公司	用於測定抗－ｃｄ２６配體的生物學活性之定量的細胞法
CN109709337B (zh) *	2018-12-28	2021-09-14	江苏众红生物工程创药研究院有限公司	人cd26的免疫组化检测试剂盒及其临床应用
EP4188953A1 (en) *	2020-07-28	2023-06-07	Adienne S.A.	Treatment of idiopathic inflammatory myopathies
AU2022273206A1 (en) *	2021-05-13	2024-01-04	Adienne S.A.	Methods of treating dermatomyositis
WO2022238978A1 (en) *	2021-05-13	2022-11-17	Adienne S.A.	Methods of treating graft versus host disease
CN116023491A (zh) *	2021-10-25	2023-04-28	江苏众红生物工程创药研究院有限公司	抗cd26抗体及其应用
CN118359716A (zh) *	2023-01-18	2024-07-19	江苏众红生物工程创药研究院有限公司	抗cd26抗体及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4036945A (en)	1976-05-03	1977-07-19	The Massachusetts General Hospital	Composition and method for determining the size and location of myocardial infarcts
US4331647A (en)	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4704692A (en)	1986-09-02	1987-11-03	Ladner Robert C	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5567610A (en)	1986-09-04	1996-10-22	Bioinvent International Ab	Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5229275A (en)	1990-04-26	1993-07-20	Akzo N.V.	In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1993011161A1 (en)	1991-11-25	1993-06-10	Enzon, Inc.	Multivalent antigen-binding proteins
NL9400309A (nl) *	1993-11-04	1995-06-01	Eurogenetics Nv	Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26.
ATE335005T1 (de)	1998-04-15	2006-08-15	Genentech Inc	Menschliches protein mit in vitro antiproliferativer aktivität.
EP1197755A1 (en)	2000-10-11	2002-04-17	Pepscan Systems B.V.	Identification of protein binding sites
CA2446806A1 (en) *	2001-05-11	2002-11-21	Board Of Regents, The University Of Texas System	Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
PT1844337E (pt)	2005-01-24	2014-04-03	Pepscan Systems Bv	Compostos ligantes, compostos imunogénicos e peptidomiméticos
JP5214252B2 (ja)	2005-03-03	2013-06-19	イミューノメディクス、インコーポレイテッド	ヒト化ｌ２４３抗体
RU2486204C2 (ru) *	2005-07-22	2013-06-27	Уай'З Терапьютикс Ко., Лтд.	Антитела против сd26 и способы их применения
HRP20140091T4 (hr) *	2005-09-14	2021-12-24	Takeda Pharmaceutical Company Limited	Davanje inhibitora dipeptidil peptidaze
US8846393B2 (en) *	2005-11-29	2014-09-30	Gamida-Cell Ltd.	Methods of improving stem cell homing and engraftment
RU2331881C1 (ru) *	2007-03-09	2008-08-20	ГОУ ВПО "Красноярская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию"	Способ определения риска развития атопических заболеваний у новорожденных детей
MX2011003183A (es)	2008-09-26	2011-04-21	Oncomed Pharm Inc	Agentes que se unen a receptor encrespado y usos de los mismos.
CN103167870B (zh) *	2010-08-18	2018-11-16	T·迭舍尔	抑制干细胞和祖细胞与淋巴样组织结合和用于使淋巴组织中的生发中心再生的组合物和方法
EP2767549A1 (en) *	2013-02-19	2014-08-20	Adienne S.A.	Anti-CD26 antibodies and uses thereof

2013
- 2013-02-19 EP EP13425029.9A patent/EP2767549A1/en not_active Withdrawn
2014
- 2014-02-19 RU RU2014153440A patent/RU2662933C2/ru active
- 2014-02-19 HR HRP20191277T patent/HRP20191277T8/hr unknown
- 2014-02-19 KR KR1020147035708A patent/KR101869589B1/ko active Active
- 2014-02-19 PL PL14705767T patent/PL2864359T3/pl unknown
- 2014-02-19 US US14/184,241 patent/US9376498B2/en active Active
- 2014-02-19 SM SM20190408T patent/SMT201900408T1/it unknown
- 2014-02-19 CN CN201480002117.1A patent/CN104684931B/zh active Active
- 2014-02-19 SI SI201431259T patent/SI2864359T1/sl unknown
- 2014-02-19 NZ NZ631111A patent/NZ631111A/en unknown
- 2014-02-19 WO PCT/EP2014/053243 patent/WO2014128168A1/en not_active Ceased
- 2014-02-19 RS RS20190938A patent/RS59093B1/sr unknown
- 2014-02-19 PT PT14705767T patent/PT2864359T/pt unknown
- 2014-02-19 ES ES14705767T patent/ES2738283T3/es active Active
- 2014-02-19 HU HUE14705767A patent/HUE045150T2/hu unknown
- 2014-02-19 TR TR2019/10572T patent/TR201910572T4/tr unknown
- 2014-02-19 LT LTEP14705767.3T patent/LT2864359T/lt unknown
- 2014-02-19 EP EP19170670.4A patent/EP3536711A1/en not_active Withdrawn
- 2014-02-19 ME MEP-2019-212A patent/ME03753B/me unknown
- 2014-02-19 CA CA2874422A patent/CA2874422C/en active Active
- 2014-02-19 AU AU2014220777A patent/AU2014220777B2/en active Active
- 2014-02-19 MX MX2014014935A patent/MX357293B/es active IP Right Grant
- 2014-02-19 EP EP14705767.3A patent/EP2864359B1/en active Active
- 2014-02-19 JP JP2015529076A patent/JP6240195B2/ja active Active
- 2014-02-19 DK DK14705767.3T patent/DK2864359T3/da active
2015
- 2015-02-16 IL IL237244A patent/IL237244B/en active IP Right Grant
- 2015-04-07 SA SA515360248A patent/SA515360248B1/ar unknown
2016
- 2016-05-31 US US15/169,386 patent/US10208126B2/en active Active
2017
- 2017-07-10 JP JP2017134896A patent/JP2017221205A/ja active Pending
2019
- 2019-07-22 CY CY20191100774T patent/CY1121980T1/el unknown

Also Published As

Publication number	Publication date
SMT201900408T1 (it)	2019-09-09
EP2767549A1 (en)	2014-08-20
ME03753B (me)	2021-04-20
HRP20191277T8 (hr)	2019-11-01
WO2014128168A1 (en)	2014-08-28
CN104684931A (zh)	2015-06-03
RU2662933C2 (ru)	2018-07-31
KR20150023419A (ko)	2015-03-05
JP2015529204A (ja)	2015-10-05
MX357293B (es)	2018-07-04
EP2864359B1 (en)	2019-04-24
HRP20191277T1 (hr)	2019-10-18
US20160264676A1 (en)	2016-09-15
LT2864359T (lt)	2019-09-25
MX2014014935A (es)	2015-06-17
CN104684931B (zh)	2019-08-27
TR201910572T4 (tr)	2019-08-21
IL237244B (en)	2019-09-26
US10208126B2 (en)	2019-02-19
CY1121980T1 (el)	2020-10-14
KR101869589B1 (ko)	2018-06-20
EP2864359A1 (en)	2015-04-29
PT2864359T (pt)	2019-07-26
NZ631111A (en)	2017-06-30
RS59093B1 (sr)	2019-09-30
SI2864359T1 (sl)	2019-09-30
AU2014220777B2 (en)	2017-03-16
US9376498B2 (en)	2016-06-28
SA515360248B1 (ar)	2017-02-20
JP2017221205A (ja)	2017-12-21
ES2738283T3 (es)	2020-01-21
PL2864359T3 (pl)	2019-11-29
HUE045150T2 (hu)	2019-12-30
JP6240195B2 (ja)	2017-11-29
HK1205151A1 (en)	2015-12-11
AU2014220777A1 (en)	2014-11-27
IL237244A0 (en)	2015-04-30
RU2014153440A (ru)	2016-07-20
CA2874422A1 (en)	2014-08-28
US20150017178A1 (en)	2015-01-15
CA2874422C (en)	2021-10-19
EP3536711A1 (en)	2019-09-11
BR112015002130A2 (pt)	2017-11-07

Publication	Publication Date	Title
IL290972A (en)	2022-05-01	Anti-vista antibodies and fragments
DK2970460T3 (da)	2020-06-02	Anti-IL-33-antistoffer og anvendelser deraf
DK3043784T3 (da)	2019-07-15	Arylethere og anvendelser deraf
DK3089994T3 (da)	2022-07-04	Fabs-in-tandem-immunglobulin og anvendelser deraf
DK3027209T3 (da)	2020-11-02	Anti-Activin A-antistoffer og anvendelser deraf
DK3003039T3 (da)	2021-05-25	Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3199552T3 (da)	2020-03-30	Anti-ceacam5-antistoffer og anvendelser heraf
DK2914291T3 (da)	2022-05-16	Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2968552T3 (da)	2020-04-14	Targeteringsmiddel-antistofkonjugater og anvendelser deraf
DK3019240T3 (da)	2024-06-03	Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
DK3336192T3 (da)	2022-03-14	Rna-transskriptionsvektor og anvendelser deraf
DK3027204T3 (da)	2022-04-19	Flerdelte signaleringsproteiner og anvendelser deraf
DK3026062T3 (da)	2020-10-12	Anti-pd-1-antistof og anvendelse deraf
DK2962100T3 (da)	2021-11-01	Tuberkulosebiomarkører og anvendelser deraf
DK2864359T3 (da)	2019-07-22	Anti-cd26-antistoffer og anvendelser deraf
IL245036B (en)	2020-10-29	Pesticidal compositions and related methods
DK3063144T3 (da)	2021-10-25	Antiparasitære og pesticid-isoxazolinforbindelser
DK3079719T3 (da)	2019-11-18	ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK3086807T3 (da)	2022-09-19	Antistoffer og fremgangsmåder til anvendelse
DK2951183T3 (da)	2019-06-03	Spiro-lactam-nmda-receptormodulatorer og anvendelser heraf
DK3030549T3 (da)	2019-05-13	Pyridazinonforbindelser og anvendelser deraf
DK3453723T3 (da)	2021-09-13	Anti-ASIC1-antistoffer og anvendelser deraf
DK3029038T3 (da)	2019-05-27	Tetrazolinonforbindelse og anvendelse deraf
DK2956476T3 (da)	2020-02-17	Ligandbindende molekyler og anvendelser deraf
DK2947141T3 (da)	2019-12-09	Mikroorganismer der fremstiller docosahexaensyre og anvendelse deraf